Common Contracts
3 similar Agreement and Plan of Merger contracts by Adaptimmune Therapeutics PLC, Akari Therapeutics PLC, Peak Bio, Inc.
AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • March 5th, 2024 • Peak Bio, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 4, 2024, is among Akari Therapeutics, Plc (“Parent”), a public company limited by shares incorporated in England and Wales, Pegasus Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and a wholly owned subsidiary of Parent, and Peak Bio, Inc. (the “Company”), a Delaware corporation.
AGREEMENT AND PLAN OF MERGER BY AND AmONG AKARI THERAPEUTICS, PLC, PEGASUS MERGER SUB, INC. AND PEAK BIO, INC. Dated as of March 4, 2024Agreement and Plan of Merger • March 5th, 2024 • Akari Therapeutics PLC • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 4, 2024, is among Akari Therapeutics, Plc (“Parent”), a public company limited by shares incorporated in England and Wales, Pegasus Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and a wholly owned subsidiary of Parent, and Peak Bio, Inc. (the “Company”), a Delaware corporation.
AGREEMENT AND PLAN OF MERGER BY AND AmONG Adaptimmune therapeutics plc, AND tcr2 therapeutics inc. Dated as of March 5, 2023Agreement and Plan of Merger • March 6th, 2023 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 5, 2023, is among Adaptimmune Therapeutics plc (“Parent”), a public limited company incorporated in England and Wales, CM Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and an indirect wholly-owned subsidiary of Parent, and TCR2 Therapeutics Inc. (the “Company”), a Delaware corporation.
